Traditional Chinese Medicine has played an important role in the treatment of COVID-19 in China. As the first batch of national Chinese medicine team in China, the authors shared their experience of treating severe COVID-19 cases with TCM at Jinyintan Hospital in Wuhan, the epicenter of the outbreak in China. Twenty severe cases have been selected and reported in this book. The medical history, inspection results and treatment rationales have been described in detail, adequately illustrated with color pictures of the tongues.The book is organized as follows: The etiology and pathogenesis from TCM perspectives are comprehensively discussed in the introduction. Part I includes various theories of different experts. Part II presents reports of the clinical cases one by one.

Traditional Chinese medicine (TCM) originated from the traditional medical system in the Chinese civilization, with influences from the Daoist and Chinese folk traditions in bodily cultivation and longevity techniques. In the past few decades, TCM has become one of the leading alternative medical systems in the United States. This book demonstrates the fluidity of a medical ideological system with a rich history of methodological development and internal theoretical conflicts, continuing to transform in our postmodern world where people and ideas transcend geographic, ethnic, and linguistic limitations. The unique historical trajectories and cultural dynamics of the American society are crticial nutrients for the localization of TCM, while the constant traffic of travelers and immigrants foster the globalizing tendency of TCM. The practitioners in this book represent an incredible range of clinical applications, personal styles, theoretical rationalizations, and business models. What really unifies all these practitioners is not their specific practices but the goal of these practices. The shared goal is to strive for health, not just health in terms of the lack of illness but the ultimate health of achieving perfect balance in every aspect of the being of a person—physically, mentally, spiritually, and energetically.

Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries.

The result of collaboration between the University of New South Wales and the Tsinghua University in Beijing, this unique chronicle maps some of the most important social, political, and cultural characteristics of the HIV epidemic in China. Demonstrating that the epidemic was propelled by three main economic drivers--the blood trade, the drug trade, and the sex trade--this informative compilation of essays uncovers the hidden truths about the spread of HIV and analyzes its social impacts.

Drug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined. As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation document. The methods to detect drug targets are described in the first volume of this series "Pharmacological Assays" comprising classical methods as well as new technologies. Before going to man, the most suitable compound has to be selected by pharmacokinetic studies and experiments in toxicology. These preclinical methods are described in the second volume „Safety and Pharmacokinetic Assays". Only then are first studies in human beings allowed. Special rules are established for Phase I studies. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: „Methods in Clinical Pharmacology".

This new clinical resource clearly explains how to approach integrated care in a way that combines Chinese herbal medicine with Western medicine to enhance and improve medical care for patients with cancer - without undermining or negatively impacting patients' medical treatment. Each chapter covers a different type of cancer, first introducing the conventional medical understanding of that cancer including its etiology, diagnosis, and treatment according to staging and type. The chapter then covers that cancer from the perspective of Oriental medicine. Case studies illustrate the integration of treatment for each cancer type, raising important issues and considerations associated with specific cancers and treatments. Formulas are presented within the context of conventional treatment, intended to enhance the effectiveness of treatment and/or treat side effects without undermining the treatment's function. Each formula is followed by a discussion of how and why the herbs are used, including classical Chinese theory and relevant pharmaceutical studies. Staging and the age and performance status of various patients is used as a means by which to explain how formulas are changed. Case studies explore issues related to the integration of treatment for each type of cancer.